<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17388" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alosetron</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Butt</surname>
            <given-names>Ifrah</given-names>
          </name>
          <aff>Aventura Hospital and Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasmin</surname>
            <given-names>Franklin</given-names>
          </name>
          <aff>Mount Sinai School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ifrah Butt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Franklin Kasmin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17388.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Alosetron&#x000a0;is a 5-HT3 receptor antagonist&#x000a0;that treats severe diarrhea-predominant irritable bowel syndrome (IBS-D). This educational activity focuses on the indications, mechanism of action, and contraindications associated with alosetron. Participants will also review the FDA-issued box warnings, adverse event profiles, toxicity, and critical considerations such as dosing, monitoring, and relevant drug interactions. Understanding alosetron's pharmacological features&#x000a0;significantly enhances&#x000a0;healthcare professionals' ability to tailor treatment plans to individual patient needs. Reviewing this information can help&#x000a0;interprofessional healthcare team members deliver targeted, safe, and personalized care, improving outcomes&#x000a0;for patients&#x000a0;receiving alosetron therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of alosetron.</p></list-item><list-item><p>Evaluate the adverse drug reactions&#x000a0;associated with&#x000a0;alosetron administration.</p></list-item><list-item><p>Assess the appropriate monitoring protocols for patients&#x000a0;receiving&#x000a0;alosetron therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve treatment efficacy&#x000a0;and outcomes for&#x000a0;patients with IBS-D who might benefit from alosetron&#x000a0;therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17388&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17388">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17388.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Diarrhea-predominant irritable bowel syndrome (IBS-D) is a functional disorder of the gastrointestinal tract (GI) that manifests with chronic abdominal pain and diarrhea.&#x000a0;This&#x000a0;condition negatively impacts the quality of life of individual&#x000a0;affected patients and contributes to increasing healthcare costs nationwide.<xref ref-type="bibr" rid="article-17388.r1">[1]</xref>&#x000a0;The first-line&#x000a0;management for IBS-D&#x000a0;typically involves diet and lifestyle modifications. Alosetron initially&#x000a0;received FDA approval in February 2000&#x000a0;as a treatment for women with IBS-D.<xref ref-type="bibr" rid="article-17388.r2">[2]</xref><xref ref-type="bibr" rid="article-17388.r3">[3]</xref>&#x000a0;However, it was temporarily withdrawn due to&#x000a0;gastrointestinal adverse effects, including&#x000a0;severe complications of constipation (CoC) and instances of ischemic colitis (IC).&#x000a0;Alosetron was reintroduced in June 2002 under strict prescribing guidelines and a risk evaluation and mitigation strategy (REMS).<xref ref-type="bibr" rid="article-17388.r4">[4]</xref><xref ref-type="bibr" rid="article-17388.r5">[5]</xref><xref ref-type="bibr" rid="article-17388.r6">[6]</xref> The FDA no longer&#x000a0;requires&#x000a0;a&#x000a0;REMS&#x000a0;before&#x000a0;prescribing alosetron.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Alosetron was reintroduced in 2002,&#x000a0;and its use is restricted&#x000a0;to treating women with severe IBS-D symptoms that are refractory to other therapies.<xref ref-type="bibr" rid="article-17388.r7">[7]</xref></p>
        <p>A diagnosis of severe IBS-D&#x000a0;requires diarrhea and&#x000a0;1 or more of the following:<xref ref-type="bibr" rid="article-17388.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Frequent and severe abdominal pain and discomfort&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Frequent bowel urgency and fecal incontinence</p>
          </list-item>
          <list-item>
            <p>Disability or restrictions in activities of daily living as a result of IBS symptoms</p>
          </list-item>
        </list>
        <p>The Rome IV diagnostic questionnaire for adults&#x000a0;demonstrates&#x000a0;a sensitivity of 62.7% and&#x000a0;a specificity of 94.5% for IBS.<xref ref-type="bibr" rid="article-17388.r9">[9]</xref></p>
        <p>To be started on alosetron, women with severe IBS-D&#x000a0;must have:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic symptoms (6 months or longer)</p>
          </list-item>
          <list-item>
            <p>No increased risk for&#x000a0;ischemic colitis or complications of constipation as a result of abnormal GI anatomy or biochemistry</p>
          </list-item>
          <list-item>
            <p>Symptoms&#x000a0;refractory to conventional therapy</p>
          </list-item>
        </list>
        <p>Upon its reintroduction,&#x000a0;the recommended initial dose of alosetron was also&#x000a0;reduced to minimize the incidence of constipation.<xref ref-type="bibr" rid="article-17388.r6">[6]</xref><bold>&#x000a0;</bold>The American Gastroenterological Association (AGA) recommends considering alosetron&#x000a0;for patients diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D). This recommendation is conditional and based on moderate certainty of evidence.<xref ref-type="bibr" rid="article-17388.r10">[10]</xref>&#x000a0;The American College of Obstetricians and Gynecologists (ACOG) recognizes alosetron as a treatment for patients with IBS-D. Extensive study data reinforce its&#x000a0;effectiveness&#x000a0;in&#x000a0;improving&#x000a0;symptoms, particularly in women.<xref ref-type="bibr" rid="article-17388.r11">[11]</xref>&#x000a0;The United European Gastroenterology and European Society for Neurogastroenterology and Motility guidelines recommend using 5-HT3 antagonists such as alosetron&#x000a0;to treat irritable bowel syndrome with diarrhea (IBS-D). However, no evidence currently supports the administration of these agents for patients with functional diarrhea.<xref ref-type="bibr" rid="article-17388.r12">[12]</xref></p>
      </sec>
      <sec id="article-17388.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Irritable bowel syndrome is a complex condition with an unclear etiopathogenesis. Researchers have postulated that serotonin&#x000a0;is&#x000a0;involved in the mechanism of IBS because&#x000a0;more than 90% of the body's serotonin is present in the enterochromaffin cells of the GI tract.<xref ref-type="bibr" rid="article-17388.r13">[13]</xref>&#x000a0;The enterochromaffin cells release serotonin in response to chemical and barometric stimuli, activating peristaltic and secretory reflexes.<xref ref-type="bibr" rid="article-17388.r14">[14]</xref></p>
        <p>Alosetron is a 5-hydroxytryptamine 3 (5-HT3, or serotonin) receptor antagonist that blocks these receptors, inhibiting peristalsis and slowing colonic transit time, allowing increased water reabsorption and stool formation.<xref ref-type="bibr" rid="article-17388.r6">[6]</xref><xref ref-type="bibr" rid="article-17388.r13">[13]</xref>&#x000a0;In patients with IBS-D, blockade of these receptors reduces pain, abdominal discomfort, urgency, and diarrhea.&#x000a0;This blockade also&#x000a0;decreases visceral hypersensitivity by reducing blood flow to the brain's emotional centers, which helps&#x000a0;regulate the emotional component of visceral stimulation.<xref ref-type="bibr" rid="article-17388.r15">[15]</xref><xref ref-type="bibr" rid="article-17388.r16">[16]</xref><xref ref-type="bibr" rid="article-17388.r17">[17]</xref>&#x000a0;Alosetron&#x000a0;prolongs&#x000a0;colonic transit without&#x000a0;affecting oro-cecal transit time and enhances basal water and sodium absorption in the jejunum,&#x000a0;providing benefits for patients with IBS-D.<xref ref-type="bibr" rid="article-17388.r18">[18]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Alosetron&#x000a0;demonstrates rapid oral absorption and&#x000a0;has an absolute bioavailability&#x000a0;of&#x000a0;50% to 60%. Peak plasma concentrations are typically attained&#x000a0;within an hour. Alosetron absorption rates&#x000a0;are reduced by&#x000a0;approximately 25%&#x000a0;if taken with food, causing a delay in the time to peak plasma concentration by approximately 15 minutes. Despite equal dosing, plasma concentrations are 27% lower in men&#x000a0;than women. Population pharmacokinetic studies of patients with IBS have confirmed this difference.</p>
        <p><bold>Distribution:</bold>&#x000a0;Alosetron's volume of distribution ranges from 65 to 95 L,&#x000a0;with 82% plasma protein binding.</p>
        <p><bold>Metabolism:</bold> Alosetron is primarily&#x000a0;metabolized by cytochrome P450 enzymes, including CYP2C9, CY3A4, and CYP1A2. Non-CYP-mediated Phase I mechanisms&#x000a0;account for about 11% of alosetron metabolism. In vivo studies have shown that CYP1A2 plays a significant role in alosetron metabolism.<xref ref-type="bibr" rid="article-17388.r19">[19]</xref>&#x000a0;The coadministration of some drugs and lifestyle factors, such as smoking, can influence CYP1A2 activity and affect alosetron clearance.</p>
        <p><bold>Elimination:</bold> The terminal elimination half-life of alosetron is approximately 1.5 hours.&#x000a0;Studies involving&#x000a0;radiolabeled alosetron&#x000a0;have demonstrated that 74% (&#x000b1;5%) is&#x000a0;eliminated&#x000a0;through urine,&#x000a0;primarily as the 6-hydroxy glucuronide and oxygenated imidazole derivatives. Fecal excretion accounts for 11% (&#x000b1;4%),&#x000a0;and less than 1% is excreted unchanged.</p>
      </sec>
      <sec id="article-17388.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Alosetron is&#x000a0;available as a&#x000a0;0.5 or&#x000a0;1 mg oral tablet.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The recommended initial dose is 0.5 mg twice daily to minimize constipation risk. If constipation occurs, the medication is discontinued until symptoms resolve. Patients&#x000a0;may be restarted on 0.5 mg once daily; alosetron should be discontinued if constipation recurs at this dose.<xref ref-type="bibr" rid="article-17388.r20">[20]</xref><xref ref-type="bibr" rid="article-17388.r21">[21]</xref>&#x000a0;</p>
        <p>Patients can&#x000a0;remain on 0.5 mg once or twice daily dosing if their symptoms are well-controlled. If symptoms&#x000a0;remain uncontrolled&#x000a0;after&#x000a0;4 weeks at this dose,&#x000a0;alosetron can be increased to 1 mg twice daily. If symptoms persist after&#x000a0;4 weeks despite this increased dosing, alosetron should be discontinued.<xref ref-type="bibr" rid="article-17388.r20">[20]</xref></p>
        <p>
<bold>Dosage Adjustment for Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Constipation:</bold> Patients experiencing constipation&#x000a0;at&#x000a0;0.5 mg twice daily must discontinue the medication immediately until symptoms resolve. The drug may be restarted at 0.5 mg once daily. If constipation recurs at this lower dose, alosetron must be discontinued immediately.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ischemic colitis:</bold>&#x000a0;Alosetron should be discontinued immediately without restarting.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Debilitated patients:</bold>&#x000a0;Alosetron should be administered&#x000a0;cautiously due to the increased risk of complications from constipation.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No dosage adjustments are necessary for mild to moderate impairment (Child-Pugh class A or B).&#x000a0;Caution is advised due to alosetron's extensive hepatic metabolism via CYP2C9, 3A4, and 1A2 enzymes. Alosetron is contraindicated for patients with severe hepatic impairment (Child-Pugh class C).</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustments are necessary.</p>
        <p><bold>Pregnancy considerations:</bold> Alosetron is&#x000a0;a former US FDA pregnancy category B medication. Studies&#x000a0;involving&#x000a0;alosetron hydrochloride administration during organogenesis in rat and rabbit models showed no adverse developmental effects at 160 and 240 times the recommended human dosage.&#x000a0;However, due to insufficient data on pregnant women receiving alosetron, the risk of potential adverse maternal or fetal outcomes cannot be adequately assessed. Therefore,&#x000a0;the potential benefits should weighed against these unknown risks before administering alosetron to women who are pregnant.<xref ref-type="bibr" rid="article-17388.r11">[11]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> No information is currently available regarding alosetron administration to&#x000a0;women who are breastfeeding. Due to its high protein binding and moderate bioavailability, infant exposure through breast milk is considered&#x000a0;minimal. Until more data&#x000a0;is available, alosetron should be administered cautiously&#x000a0;to women who are breastfeeding. The infant should be monitored for constipation or blood in the stool.<xref ref-type="bibr" rid="article-17388.r22">[22]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Alosetron is not recommended in pediatric patients due to the increased risk of serious complications such as constipation and ischemic colitis observed in adults.</p>
        <p><bold>Older patients:</bold>&#x000a0;Older patients may be at an increased risk of constipation-related complications; caution and regular monitoring are advised when prescribing alosetron to these patients.</p>
      </sec>
      <sec id="article-17388.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effect&#x000a0;associated with alosetron administration is constipation. A randomized, double-blind, placebo-controlled study assessed the efficacy and safety of&#x000a0;alosetron 0.5 mg and 1 mg in women with severe IBS-D. The study data revealed that constipation occurred in patients receiving&#x000a0;0.5 mg (9%), 1 mg once daily (16%), and 1 mg twice daily (19%).<xref ref-type="bibr" rid="article-17388.r21">[21]</xref></p>
        <p>Other common adverse effects associated with alosetron therapy include:<xref ref-type="bibr" rid="article-17388.r23">[23]</xref><xref ref-type="bibr" rid="article-17388.r24">[24]</xref><xref ref-type="bibr" rid="article-17388.r25">[25]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal discomfort and pain</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Abdominal distension</p>
          </list-item>
          <list-item>
            <p>Regurgitation and reflux</p>
          </list-item>
          <list-item>
            <p>Hemorrhoids</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
        </list>
        <p>Although rare, ischemic colitis&#x000a0;has been reported in patients taking alosetron&#x000a0;to treat IBS. Clinical trials comparing patients receiving alosetron 1 mg twice daily to patients receiving placebo showed that the cumulative incidence of ischemic colitis was 0.2% within the first&#x000a0;3 months and 0.3% within the first&#x000a0;6 months.<xref ref-type="bibr" rid="article-17388.r26">[26]</xref>&#x000a0;A statistically significant increase in the incidence of ischemic colitis was observed&#x000a0;in the pooled data of clinical trials&#x000a0;involving&#x000a0;patients&#x000a0;receiving alosetron compared with placebo (0.15%&#x000a0;vs&#x000a0;0.00%,&#x000a0;<italic toggle="yes">p</italic>=0.03).<xref ref-type="bibr" rid="article-17388.r4">[4]</xref>&#x000a0;No precise mechanism for this observation is known, but many have been hypothesized. One possible mechanism involves the blockade of 5-HT3 receptors,&#x000a0;increasing free&#x000a0;serotonin available to stimulate other serotonin receptors (ie, 5-HT1 and 5-HT2) that may be involved in vasoconstriction.<xref ref-type="bibr" rid="article-17388.r27">[27]</xref>&#x000a0;This vasoconstriction may increase the risk of developing ischemic colitis in&#x000a0;patients with concomitant atherosclerotic disease in vessels feeding the GI tract.<xref ref-type="bibr" rid="article-17388.r28">[28]</xref>&#x000a0;Another hypothesis&#x000a0;postulates that ischemic colitis may result from&#x000a0;alosetron's effects on colonic motility and intestinal blood flow. Because alosetron is associated with severe constipation, patients with existing vascular disease may be&#x000a0;at increased risk of developing intestinal ischemia.<xref ref-type="bibr" rid="article-17388.r29">[29]</xref>&#x000a0;These predictions are based on observations of animal models and have not been studied in humans.</p>
        <p>Gastrointestinal adverse reactions&#x000a0;are common in postmarketing surveillance studies.&#x000a0;GI perforation, impaction, ulceration, small bowel mesenteric ischemia, headache, and skin rash have been reported in patients receiving alosetron.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>CYP1A2 inhibitors:</bold> Fluvoxamine, a potent CYP1A2 inhibitor, can inhibit the metabolism of alosetron if coadministered, leading to alosetron toxicity. Fluvoxamine can increase the mean plasma concentration&#x000a0;of alosetron by 6-fold and prolong the half-life by 3-fold.<xref ref-type="bibr" rid="article-17388.r24">[24]</xref>&#x000a0;Moderate CYP1A2 inhibitors (eg, cimetidine, quinolone antibiotics) should be avoided unless clinically indicated.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>CYP3A4 inhibitors:</bold> Ketoconazole,&#x000a0;clarithromycin, telithromycin, voriconazole, itraconazole, and protease inhibitors are strong CYP3A4 inhibitors and may increase alosetron toxicity. Due to potential drug interactions, clinicians should exercise caution when administering alosetron and CYP3A4 inhibitors concomitantly.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17388.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to alosetron administration include:<xref ref-type="bibr" rid="article-17388.r21">[21]</xref><xref ref-type="bibr" rid="article-17388.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic or severe constipation or any sequelae from constipation</p>
          </list-item>
          <list-item>
            <p>Intestinal obstruction or stricture</p>
          </list-item>
          <list-item>
            <p>Toxic megacolon</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal perforation or adhesions</p>
          </list-item>
          <list-item>
            <p>Diverticulitis</p>
          </list-item>
          <list-item>
            <p>Crohn disease or ulcerative colitis</p>
          </list-item>
          <list-item>
            <p>Ischemic colitis</p>
          </list-item>
          <list-item>
            <p>Thrombophlebitis</p>
          </list-item>
          <list-item>
            <p>Impaired intestinal circulation</p>
          </list-item>
          <list-item>
            <p>Severe hepatic impairment</p>
          </list-item>
          <list-item>
            <p>Hypercoagulable state</p>
          </list-item>
          <list-item>
            <p>Patients receiving&#x000a0;fluvoxamine</p>
          </list-item>
        </list>
        <p>
<bold>Box Warnings</bold>
</p>
        <p><bold>Severe&#x000a0;gastrointestinal adverse reactions:&#x000a0;</bold>Alosetron hydrochloride is indicated only for severe diarrhea-predominant irritable bowel syndrome (IBS) in women who have not responded adequately to standard therapy.&#x000a0;Severe gastrointestinal adverse reactions, including ischemic colitis and complications of constipation, have been reported. These events have led to hospitalization and, in rare cases, require blood transfusion or surgery or have resulted in death.</p>
        <p><bold>Complications of constipation (CoC): </bold>Intestinal obstruction, ileus, fecal impaction, and toxic megacolon have been reported with alosetron use.<xref ref-type="bibr" rid="article-17388.r26">[26]</xref>&#x000a0;Alosetron should be discontinued immediately if constipation develops. Intestinal surgery, including colectomy, may be indicated. Patients who are older, debilitated, or taking&#x000a0;medications that reduce gastrointestinal motility may be at greater risk of developing these adverse reactions.</p>
        <p><bold>Ischemic colitis:</bold>&#x000a0;Alosetron should discontinued immediately if signs of ischemic colitis are observed,&#x000a0;including rectal bleeding, bloody diarrhea, or new or worsening abdominal pain. Prompt evaluation and appropriate diagnostic testing are essential&#x000a0;as ischemic colitis is a life-threatening condition.&#x000a0;Advanced age&#x000a0;is associated with fatal outcomes.<xref ref-type="bibr" rid="article-17388.r30">[30]</xref></p>
      </sec>
      <sec id="article-17388.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Although&#x000a0;severe gastrointestinal adverse events are uncommon, patients should&#x000a0;be advised to look for alarming signs and symptoms. Alosetron therapy should be discontinued immediately&#x000a0;for any patient who develops constipation or ischemic colitis. Alosetron&#x000a0;should not be resumed for any patient who develops ischemic colitis. Patients who develop constipation&#x000a0;that does not resolve after discontinuing alosetron&#x000a0;must notify their provider immediately.<xref ref-type="bibr" rid="article-17388.r24">[24]</xref>&#x000a0;Treatment response should be monitored using validated tools such as the IBS global improvement scale (IBS-GIS) and health-related QOL.<xref ref-type="bibr" rid="article-17388.r31">[31]</xref><xref ref-type="bibr" rid="article-17388.r32">[32]</xref></p>
      </sec>
      <sec id="article-17388.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>During&#x000a0;clinical studies, doses up to 16 mg (8 times the recommended daily dose)&#x000a0;have been administered without significant adverse reactions.&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no specific antidote for alosetron.<xref ref-type="bibr" rid="article-17388.r33">[33]</xref>&#x000a0;Patients should be managed with appropriate supportive therapy. Overdose with alosetron&#x000a0;may reduce the first-pass metabolism of other drugs.&#x000a0;A poison control center should be contacted for overdose treatment protocol.</p>
      </sec>
      <sec id="article-17388.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although studies have shown that alosetron improves IBS-D symptoms, reduces pain and discomfort, and improves patients' quality of life, healthcare providers need to be mindful of the&#x000a0;severe adverse effects&#x000a0;associated with this medication.<xref ref-type="bibr" rid="article-17388.r34">[34]</xref>&#x000a0;Physicians should rule out other GI&#x000a0;conditions before prescribing alosetron. Specially trained nurses educate patients, monitor their status, and report issues to the team. Pharmacists review the medication dose and drug-drug interactions and inform patients about potentially dangerous adverse drug reactions.&#x000a0;Ischemic colitis and complications of constipation resulting from alosetron use have resulted in hospitalization, surgery, and death. Patients&#x000a0;receiving this medication must be monitored closely and advised of the possible symptoms to monitor and prevent&#x000a0;severe complications. Nurses can verify patient compliance, monitor for adverse events, document therapeutic responses, and inform clinicians of concerns. Gastroenterologists should be consulted for patients with ischemic colitis or ileus.</p>
        <p>An umbrella systematic review evaluating pharmacologic treatments for irritable bowel syndrome (IBS)&#x000a0;assessed&#x000a0;patient outcomes associated with 5-HT-3 antagonists, 5-HT4 agonists, guanylate cyclase-C agonists, antispasmodics, and alosetron. According to the review's findings, alosetron exhibited&#x000a0;beneficial effects,&#x000a0;including relief of global IBS symptoms.<xref ref-type="bibr" rid="article-17388.r35">[35]</xref></p>
        <p>The REMS program for alosetron was implemented to reduce gastrointestinal adverse events. This program restricted the prescribing of alosetron to providers enrolled in the program based on their understanding of the risks versus benefits of the medication.<xref ref-type="bibr" rid="article-17388.r16">[16]</xref>&#x000a0;The FDA eliminated the Alosetron REMS program in 2023&#x000a0;based on stable adverse event reporting&#x000a0;from its reintroduction in 2002 to 2016, consistent ischemic colitis rates in new patients, and a trend in prescriptions without increased utilization. The prescribing information&#x000a0;includes warnings regarding ischemic colitis and complications of constipation.&#x000a0;Collaboration between an interprofessional team of&#x000a0;clinicians (MDs, DOs, NPs, PAs), specialty-trained nurses, and pharmacists leads to improved patient outcomes.</p>
      </sec>
      <sec id="article-17388.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17388&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17388">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17388/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17388">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17388.s11">
        <title>References</title>
        <ref id="article-17388.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olden</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Chey</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Shringarpure</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paul Nicandro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Earnest</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>461</fpage>
            <page-range>461-472</page-range>
            <pub-id pub-id-type="pmid">30293448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Alosetron approved for treatment of irritable bowel syndrome.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2000</year>
            <month>Mar</month>
            <day>15</day>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>519</fpage>
            <pub-id pub-id-type="pmid">10754758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moshiree</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heidelbaugh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sayuk</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.</article-title>
            <source>Adv Ther</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>4003</fpage>
            <page-range>4003-4020</page-range>
            <pub-id pub-id-type="pmid">35869354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chey</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olden</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Surawicz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2006</year>
            <month>May</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>1069</fpage>
            <page-range>1069-79</page-range>
            <pub-id pub-id-type="pmid">16606352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horton</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lotronex and the FDA: a fatal erosion of integrity.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>May</month>
            <day>19</day>
            <volume>357</volume>
            <issue>9268</issue>
            <fpage>1544</fpage>
            <page-range>1544-5</page-range>
            <pub-id pub-id-type="pmid">11377636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-29</page-range>
            <pub-id pub-id-type="pmid">20136586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zakari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lembo</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Novel Therapies in IBS-D Treatment.</article-title>
            <source>Curr Treat Options Gastroenterol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>432</fpage>
            <page-range>432-40</page-range>
            <pub-id pub-id-type="pmid">26432092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lembo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ameen</surname>
                <given-names>VZ</given-names>
              </name>
              <name>
                <surname>Drossman</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Irritable bowel syndrome: toward an understanding of severity.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>717</fpage>
            <page-range>717-25</page-range>
            <pub-id pub-id-type="pmid">16233998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palsson</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>van Tilburg</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chey</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Crowell</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Keefer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lembo</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Parkman</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sperber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vanner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Whorwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians.</article-title>
            <source>Gastroenterology</source>
            <year>2016</year>
            <month>Feb</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">27144634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lembo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heidelbaugh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smalley</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Verne</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.</article-title>
            <source>Gastroenterology</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>163</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-151</page-range>
            <pub-id pub-id-type="pmid">35738725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>LaBundy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lower Gastrointestinal Tract Disorders: Clinical Updates in Women's Health Care Primary and Preventive Care Review.</article-title>
            <source>Obstet Gynecol</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>139</volume>
            <issue>6</issue>
            <fpage>1201</fpage>
            <pub-id pub-id-type="pmid">35675626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savarino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zingone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barberio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marasco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akyuz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akpinar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barboi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bodini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiarioni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cristian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corsetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Sabatino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dimitriu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Drug</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dumitrascu</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nakov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sfarti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simr&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suciu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toruner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cremon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.</article-title>
            <source>United European Gastroenterol J</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>556</fpage>
            <page-range>556-584</page-range>
            <pub-id pub-id-type="pmid">35695704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ilham</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.</article-title>
            <source>Anesth Pain Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>e42747</fpage>
            <pub-id pub-id-type="pmid">28824858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershon</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Serotonin and its implication for the management of irritable bowel syndrome.</article-title>
            <source>Rev Gastroenterol Disord</source>
            <year>2003</year>
            <volume>3 Suppl 2</volume>
            <fpage>S25</fpage>
            <page-range>S25-34</page-range>
            <pub-id pub-id-type="pmid">12776000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Derbyshire</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Suyenobu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mandelkern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Naliboff</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>1357</fpage>
            <page-range>1357-66</page-range>
            <pub-id pub-id-type="pmid">12144587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brenner</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sayuk</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-96</page-range>
            <pub-id pub-id-type="pmid">31707713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujii</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Awaga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nozawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Natsume</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takamatsu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome.</article-title>
            <source>FASEB Bioadv</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>694</fpage>
            <page-range>694-708</page-range>
            <pub-id pub-id-type="pmid">36349296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mozaffari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nikfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abdollahi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-228</page-range>
            <pub-id pub-id-type="pmid">38366822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klomp</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drozdzik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oswald</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.</article-title>
            <source>Pharmaceutics</source>
            <year>2020</year>
            <month>Dec</month>
            <day>11</day>
            <volume>12</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">33322313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cangemi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1756284819878950</fpage>
            <pub-id pub-id-type="pmid">31632456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ameen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Perschy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>1709</fpage>
            <page-range>1709-19</page-range>
            <pub-id pub-id-type="pmid">17509028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Alosetron</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>2</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">30222295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacy</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>817</fpage>
            <page-range>817-830</page-range>
            <pub-id pub-id-type="pmid">30194692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucak</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2010</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-72</page-range>
            <pub-id pub-id-type="pmid">21180598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haus</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sp&#x000e4;th</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>F&#x000e4;rber</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Spectrum of use and tolerability of 5-HT3 receptor antagonists.</article-title>
            <source>Scand J Rheumatol Suppl</source>
            <year>2004</year>
            <volume>119</volume>
            <fpage>12</fpage>
            <page-range>12-8</page-range>
            <pub-id pub-id-type="pmid">15515406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nicandro</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Shringarpure</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>344</fpage>
            <page-range>344-57</page-range>
            <pub-id pub-id-type="pmid">24003335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Vascular receptors for 5-hydroxytryptamine: distribution, function and classification.</article-title>
            <source>Pharmacol Ther</source>
            <year>1994</year>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-324</page-range>
            <pub-id pub-id-type="pmid">7972337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potenza</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Serio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montagnani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mansi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Genualdo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitolo-Chieppa</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Functional evaluation of 5-hydroxytryptamine receptor activity in rat resistance vessels.</article-title>
            <source>J Auton Pharmacol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">9730261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Effects of serotonin on intestinal secretion and motility.</article-title>
            <source>Curr Opin Gastroenterol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">11224663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bielefeldt</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.</article-title>
            <source>Dig Dis Sci</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>2655</fpage>
            <page-range>2655-65</page-range>
            <pub-id pub-id-type="pmid">27073073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ameen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bagby</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shahan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jhingran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy.</article-title>
            <source>Dig Dis Sci</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>1317</fpage>
            <page-range>1317-23</page-range>
            <pub-id pub-id-type="pmid">12870789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funaba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawanishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Higami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maruo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horikoshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ariga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fukudo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sekiguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>673939</fpage>
            <pub-id pub-id-type="pmid">34566709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappell</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Colonic toxicity of administered drugs and chemicals.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>1175</fpage>
            <page-range>1175-90</page-range>
            <pub-id pub-id-type="pmid">15180742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bradesi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Alosetron and irritable bowel syndrome.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>2089</fpage>
            <page-range>2089-98</page-range>
            <pub-id pub-id-type="pmid">14596662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17388.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review.</article-title>
            <source>J Gastrointestin Liver Dis</source>
            <year>2020</year>
            <month>Jun</month>
            <day>03</day>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-209</page-range>
            <pub-id pub-id-type="pmid">32530987</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
